Read by QxMD icon Read


Che-Kai Tsao, John Sfakianos, Bobby Liaw, Kiev Gimpel-Tetra, Margaret Kemeny, Linda Bulone, Mohammad Shahin, William Kyu Oh, Matthew David Galsky
LESSONS LEARNED: The safety and activity findings of abiraterone acetate plus prednisone treatment in black men with mCRPC were similar to results from previously conducted studies with largely white populations.Poor trial accrual continues to be a challenge in black men with mCRPC and further efforts are needed to address such underrepresentation. BACKGROUND: Self-identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration-resistant prostate cancer (mCRPC)...
October 14, 2016: Oncologist
Maxine de la Cruz, Akhila Reddy, Vishidha Balankari, Margeaux Epner, Susan Frisbee-Hume, Jimin Wu, Diane Liu, Sriram Yennurajalingam, Hilda Cantu, Janet Williams, Eduardo Bruera
BACKGROUND: Improper use, storage, and disposal of prescribed opioids can lead to diversion or accidental poisoning. Our previous study showed a large proportion of cancer patients have unsafe opioid practices. Our objective was to determine whether an improvement occurred in the patterns of use, storage, and disposal of opioids among cancer outpatients after the implementation of a patient educational program. PATIENTS AND METHODS: Our palliative care (PC) clinic provides every patient with educational material (EM) on safe opioid use, storage, and disposal every time they receive an opioid prescription...
October 14, 2016: Oncologist
Francesco Giotta, Luigi Acito, Giampiero Candeloro, Pietro Del Medico, Gennaro Gadaleta-Caldarola, Guido Giordano, Rossana Gueli, Antonio Lugini, Valentina Magri, Marta Mandarà, Giovanna Masci, Salvatore Pisconti, Mirco Pistelli, Anna Rizzi, Nello Salesi, Alessio Schirone, Giovanni Scognamiglio, Maria Tedeschi, Patrizia Zucchinelli
BACKGROUND: Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting. PATIENTS AND METHODS: Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists...
October 14, 2016: Oncologist
Yu-Ning Wong, Nancy Roach, Neal J Meropol
No abstract text is available yet for this article.
October 14, 2016: Oncologist
Khurum Khan, Avani Athauda, Katharine Aitken, David Cunningham, David Watkins, Naureen Starling, Gary J Cook, Eleftheria Kalaitzaki, Ian Chau, Sheela Rao
BACKGROUND: This study had two aims: (a) to evaluate the utility of fluorine 18-fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography (CT) in detecting occult disease recurrence with raised carcinoembryonic antigen (CEA) and (b) to establish the prognostic effects of early detection of disease recurrence in patients with colorectal cancer (CRC). PATIENTS AND METHODS: Clinico-pathological data were obtained from all consecutive patients undergoing CRC surveillance from 2004 to 2010 who had an elevated CEA level (>3 ng/mL in nonsmokers, >5 ng/mL in smokers) but normal or equivocal conventional investigations...
October 14, 2016: Oncologist
Andrew Rankin, Samuel J Klempner, Rachel Erlich, James X Sun, Axel Grothey, Marwan Fakih, Thomas J George, Jeeyun Lee, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Siraj M Ali, Alexa B Schrock
INTRODUCTION: A KRAS mutation represented the first genomic biomarker to predict lack of benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy in advanced colorectal cancer (CRC). Expanded RAS testing has further refined the treatment approach, but understanding of genomic alterations underlying primary and acquired resistance is limited and further study is needed. MATERIALS AND METHODS: We prospectively analyzed 4,422 clinical samples from patients with advanced CRC, using hybrid-capture based comprehensive genomic profiling (CGP) at the request of the individual treating physicians...
September 28, 2016: Oncologist
Sander Bins, Geert A Cirkel, Christa G Gadellaa-van Hooijdonk, Fleur Weeber, Isaac J Nijman, Annette H Bruggink, Paul J van Diest, Stefan M Willems, Wouter B Veldhuis, Michel M van den Heuvel, Rob J de Knegt, Marco J Koudijs, Erik van Werkhoven, Ron H J Mathijssen, Edwin Cuppen, Stefan Sleijfer, Jan H M Schellens, Emile E Voest, Marlies H G Langenberg, Maja J A de Jonge, Neeltje Steeghs, Martijn P Lolkema
BACKGROUND: The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis...
September 23, 2016: Oncologist
Emmanuel S Antonarakis, Chandtip Chandhasin, Erica Osbourne, Jun Luo, Marianne D Sadar, Frank Perabo
: : Despite the recent approval and widespread use of abiraterone acetate and enzalutamide for the treatment of castration-resistant prostate cancer (CRPC), this disease still poses significant management challenges because of various tumor escape mechanisms, including those that allow androgen receptor (AR) signaling to remain active. These AR-related resistance mechanisms include AR gene amplification or overexpression, constitutively active ligand-independent AR splice variants, and gain-of-function mutations involving the AR ligand-binding domain (LBD), among others...
September 14, 2016: Oncologist
Jingbo Wang, Zongmei Zhou, Jun Liang, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Xiaozhen Wang, Jima Lv, Dongfu Chen, Hongxing Zhang, Zhe Ji, Jianzhong Cao, Lipin Liu, Wei Jiang, Yu Men, Cai Xu, Jiangrong Dai, Weibo Yin, Luhua Wang
BACKGROUND: Consistent results are lacking as regards the comparative effectiveness of intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). PATIENTS AND METHODS: Patients treated with definitive radiotherapy (RT) between 2002 and 2010 were retrospectively reviewed. Overall survival (OS), local-regional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) were compared among patients irradiated with different techniques...
September 14, 2016: Oncologist
Kim M Hirshfield, Denis Tolkunov, Hua Zhong, Siraj M Ali, Mark N Stein, Susan Murphy, Hetal Vig, Alexei Vazquez, John Glod, Rebecca A Moss, Vladimir Belyi, Chang S Chan, Suzie Chen, Lauri Goodell, David Foran, Roman Yelensky, Norma A Palma, James X Sun, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Howard Kaufman, Elizabeth Poplin, Janice Mehnert, Antoinette R Tan, Joseph R Bertino, Joseph Aisner, Robert S DiPaola, Lorna Rodriguez-Rodriguez, Shridar Ganesan
BACKGROUND: The frequency with which targeted tumor sequencing results will lead to implemented change in care is unclear. Prospective assessment of the feasibility and limitations of using genomic sequencing is critically important. METHODS: A prospective clinical study was conducted on 100 patients with diverse-histology, rare, or poor-prognosis cancers to evaluate the clinical actionability of a Clinical Laboratory Improvement Amendments (CLIA)-certified, comprehensive genomic profiling assay (FoundationOne), using formalin-fixed, paraffin-embedded tumors...
August 26, 2016: Oncologist
Brittany L Bychkovsky, Hao Guo, Jazmine Sutton, Laura Spring, Jennifer Faig, Ibiayi Dagogo-Jack, Chiara Battelli, Mary Jane Houlihan, Tsai-Chu Yeh, Steven E Come, Nancy U Lin
BACKGROUND: Despite guideline recommendations, baseline laboratory testing and advanced imaging are widely ordered in clinical practice to stage asymptomatic patients with clinical stage II breast cancer (BC). MATERIALS AND METHODS: A retrospective study at two academic centers in Boston, Massachusetts, between 2006 and 2007 explored the use, results, and implications of laboratory tests, tumor markers, and imaging in patients with clinical stage II BC. RESULTS: Among 411 patients, 233 (57%) had liver function testing, 134 (33%) had tumor marker tests, and 237 (58%) had computed tomography (CT) as part of their initial diagnostic workup...
August 22, 2016: Oncologist
Arlindo R Ferreira, Irina Alho, Ning Shan, Margarida Matias, Mariana Faria, Sandra Casimiro, Kim Leitzel, Suhail Ali, Allan Lipton, Luís Costa
BACKGROUND: Markers of bone metabolism, such as N-telopeptide of type I collagen (NTX), have been demonstrated to be prognostic in previous trials of breast cancer (BC) patients with bone metastases (BMs). In the present study, we tested the survival effect of the NTX response to zoledronic acid (ZA) at 3 and 12 months in a contemporaneous cohort of BC patients with BMs and evaluated the influence of extraskeletal metastatic disease on NTX variation. PATIENTS AND METHODS: The present study was a prospective cohort study of consecutive BC patients diagnosed and treated at a single center...
August 17, 2016: Oncologist
Benjamin Herzberg, Meghan J Campo, Justin F Gainor
: : Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoints have been cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein-1 (PD-1) pathway. In early studies, PD-1/programmed cell death ligand-1 (PD-L1) inhibitors demonstrated promising antitumor activity and durable clinical responses in a subset of patients...
August 17, 2016: Oncologist
Grainne M O'Kane, Catherine Labbé, Mark K Doherty, Kelvin Young, Hamzeh Albaba, Natasha B Leighl
: : Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents...
August 17, 2016: Oncologist
Weidong Lu, Peter M Wayne, Roger B Davis, Julie E Buring, Hailun Li, Eric A Macklin, Jochen H Lorch, Elaine Burke, Tyler C Haddad, Laura A Goguen, David S Rosenthal, Roy B Tishler, Marshall R Posner, Robert I Haddad
INTRODUCTION: Dysphagia is common in head and neck cancer patients after concurrent chemoradiation therapy (CRT). This study evaluated the feasibility of conducting a randomized sham-controlled trial and collected preliminary data on safety and efficacy of acupuncture. PATIENTS AND METHODS: Head and neck cancer (HNC) patients with stage III-IV squamous cell carcinoma were randomized to 12 sessions of either active acupuncture (AA) or sham acupuncture (SA) during and following CRT...
August 10, 2016: Oncologist
Mary C Politi, Marie D Kuzemchak, Kimberly A Kaphingst, Hannah Perkins, Jingxia Liu, Margaret M Byrne
BACKGROUND: Cancer patients often do not make informed decisions regarding clinical trial participation. This study evaluated whether a web-based decision aid (DA) could support trial decisions compared with our cancer center's website. METHODS: Adults diagnosed with cancer in the past 6 months who had not previously participated in a cancer clinical trial were eligible. Participants were randomized to view the DA or our cancer center's website (enhanced usual care [UC])...
August 10, 2016: Oncologist
Xin Wang, Liang Li, Jidong Gao, Jiaqi Liu, Mingming Guo, Liyuan Liu, Wenyan Wang, Jie Wang, Zeyu Xing, Zhigang Yu, Xiang Wang
INTRODUCTION: Although obesity has been reported worldwide as a risk factor for breast cancer, there are still some inconsistencies regarding the association between obesity and breast cancer. Body mass index (BMI) is used most to assess the extent of obesity; however, the association of other body size characteristics, such as waist and hip circumference, with susceptibility to breast cancer in Chinese Han women needs to be better assessed. PATIENTS AND METHODS: Female Chinese Han patients (N = 2,800) were recruited from 21 hospitals in northern and eastern China from April 2012 to April 2013 for a case-control study...
August 5, 2016: Oncologist
Hao Peng, Lei Chen, Yuan Zhang, Wen-Fei Li, Yan-Ping Mao, Fan Zhang, Rui Guo, Li-Zhi Liu, Ai-Hua Lin, Ying Sun, Jun Ma
BACKGROUND: The objective of this study is to evaluate the prognostic value of the cumulative cisplatin dose (CCD) for long-term survival outcomes after concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: Patients were included in an open-label phase 3 multicenter randomized controlled trial performed at seven institutions in China, and the 298 patients receiving CCRT only were assessed. Patient survival between different CCD groups were compared...
August 5, 2016: Oncologist
Scott C Howard, John McCormick, Ching-Hon Pui, Randall K Buddington, R Donald Harvey
: : High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m(2), is used to treat a range of adult and childhood cancers. Although HDMTX is safely administered to most patients, it can cause significant toxicity, including acute kidney injury (AKI) in 2%-12% of patients. Nephrotoxicity results from crystallization of methotrexate in the renal tubular lumen, leading to tubular toxicity. AKI and other toxicities of high-dose methotrexate can lead to significant morbidity, treatment delays, and diminished renal function...
August 5, 2016: Oncologist
Saad Usmani, Tahamtan Ahmadi, Yvette Ng, Annette Lam, Avinash Desai, Ravi Potluri, Maneesha Mehra
BACKGROUND: This retrospective study evaluated the treatment patterns in and overall survival (OS) of multiple myeloma (MM) patients who were refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) or who had received three or more prior lines of therapy (LOTs) including a PI and an IMiD. METHODS: Electronic health records in the IMS LifeLink and OPTUM databases were screened for indexing periods of 2000-2014 and 2007-2014, respectively. Patients who were refractory to both a PI and an IMiD (criterion 1) or who received three or more prior LOTs (including a PI and an IMiD) and showed disease progression within 60 days of their most recent regimen (criterion 2) comprised the eligible population...
August 2, 2016: Oncologist
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"